Protocol Ledger

NCT04181723 · Phase III · COMPLETED

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Interventional Phase III clinical trial protocol NCT04181723 sponsored by ACADIA Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-06 Enrollment: 187 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04181723
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)187 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04181723
Protocol FieldVerified Registry Value
NCT IdentifierNCT04181723
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment187 participants (ACTUAL)
Registered Start Date2019-11-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI